Polymorphisms of H-ras-1 and p53 in breast cancer and lung cancer: A meta-analysis

Environmental Health Perspectives

Volumn 105, Issue SUPPL. 4, 1997, Pages 919-926

  Weston, Ainsley ^a,b   Godbold, James H ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b Box 1057 ^*  (United States)

Author keywords

African Americans; Breast cancer; Caucasians; H ras 1; Lung cancer; Minorities; Oncogene; Polymorphisms; pP53; Susceptibility; Tumor suppressor gene

Indexed keywords

ARGININE; PROLINE;

ALLELE; BREAST CANCER; CANCER RISK; CODON; CONFERENCE PAPER; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INHERITANCE; JAPAN; LUNG CANCER; ONCOGENE H RAS; PRIORITY JOURNAL; RACE DIFFERENCE; TUMOR SUPPRESSOR GENE;

EID: 0030754662     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.97105s4919     Document Type: Conference Paper

References (81)

1. Congress of the United States and Office of Technology. Mapping Our Genes. Genomic Projects: How Big, How Fast? Baltimore, MD:Johns Hopkins University Press, 1988.
2. Nakamura Y, Leppert M, O'Connell P, Wolff R, Holm T, Culver M, Martin C, Fujimoto E, Hoff M, Kumlin E et al. Variable number of tandem repeat (VNTR) markers for human gene mapping. Science 235:1616-1622 (1987).
3. Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM, van Tuinen P, Ledbetter DH, Barker DF, Nakamura Y. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244:217 (1989).
4. Cavenee WK, Dryja TP, Phillips RA, Benedict WF, Godbout R, Gallie BL, Murphree AL, Strong LC, White RL. Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 305:779 (1983).
5. Fearon ER, Cho KR, Nigro JM, Kern SE, Simons JW, Ruppert JM, Hamilton SR, Preisinger AC, Thomas G, Kinzler KW et al. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 247:49 (1990).
6. Kinzler KW, Nilbert MC, Vogelstein B, Bryan TM, Levy DB, Kelly JS, Pressinger, AC, Hamilton SR, Hedge P, Markham A et al. Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. Science 251:1366 (1991).
7. Koufos A, Hansen MF, Lampkin BC, Workman ML, Copeland NG, Jenkins NA, Cavenee WK. Loss of alleles at loci on human chromosome 11 during genesis of Wilms' tumour. Nature 309:170 (1984).
8. Olschwang S, Laurent-Puig P, White GR, Thomas G. Germ line mutations in the first 14 exons of the adenomatous polyposis coli gene. Am J Hum Genet 52:273 (1993).
9. Spiro L, Olschwang S, Groden J, Robertson M, Samowitz W, Joslyn G, Gelben L, Thliveris A, Carlson M. Alleles of the APC gene: an attenuated form of familial polyposis. Cell 75:951 (1993).
10. Weinberg RA. Tumor suppressor genes. Science 254:1138 (1991).
11. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA-1. Science 266:66-71 (1994).
12. Castilla LH, Couch FJ, Erdos MR, Hoskins KF, Calzone K, Garber JE. Mutations in the BRCA-1 gene in families with early-onset breast and ovarian cancer. Nat Genet 8:387-91 (1994).
13. Weston A, Perrin LS, Forrester K, Hoover RN, Trump BF, Harris CC, Caporaso NE. Allelic frequency of a p53 polymorphism in human lung cancer. Cancer Epidemiol Biomarkers Prev 1:481-483 (1992).
14. Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi SI. Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis 14:1085-1089 (1993).
15. Weston A, Ling-Cawley HM, Caporaso NE, Bowman ED, Hoover RN, Trump BF, Harris CC. Determination of the allelic frequencies of an L-myr and a p53 polymorphism in human lung cancer. Carcinogenesis 15:583-587 (1994).
16. Själander A, Birgander R, Athlin L, Stenling R, Rutegard J, Beckman L, Beckman G. p53 Germ line haplotypes associated with increased risk for colorectal cancer. Carcinogenesis 16:1461-1464 (1995).
17. Birgander R, Själander A, Rannug A, Alexandrie AK, Sundberg MI, Seidegard J, Tornling G, Beckman G, Beckman L. p53 Polymorphisms and haplotypes in lung cancer. Carcinogenesis 16:2233-2236 (1995).
18. Jin X, Wu X, Roth JA, Amos CI, King TM, Branch C, Honn SE, Spitz MR. Higher lung cancer risk for younger African-Americans with the Pro/Pro p53 genotype. Carcinogenesis 16:2205-2208 (1995).
19. Murata M, Tagawa M, Kimura M, Kimura H, Watanabe S, Saisho H. Analysis of a germ line polymorphism of the p53 gene in lung cancer patients; discrete results with smoking history. Carcinogenesis 17:261-264 (1996).
20. To-Figueras J, Gené M, Gómez-Catalàn, Firvida J, Fuentes M, Rodamilans M, Huguet E, Estapé J, Corbella J. Glutathione S-transferase M1 and codon 72 p53 polymorphisms in a northwestern Mediterranean population and their relation to lung cancer susceptibility. Cancer Epidemiol Biomarkers Prev 5:337-342 (1996).
21. Felley-Bosco E, Weston A, Cawley HM, Bennet WP, Harris CC. Functional studies of a germ-line polymorphism at codon 47 within the p53 gene. Am J Hum Genet 53:752-759 (1993).
22. Heighway J, Thatcher N, Cerny T, Hasleton PS. Genetic predisposition to human lung cancer. Br J Cancer 53:453-457 (1986).
23. White GRM, Santibanez-Koref M, Heighway J. Constitutional frequencies of c-Ha-ras alleles in patients with different types of lung cancer. Br J Cancer 61:186 (1990)
24. Sugimura H, Caporaso NE, Hoover RN, Modali R, Resau J, Trump BF, Lonergan JA, Krontiris TG, Mann DL, Weston A et al. Association of rare alleles of the Harvey-ras protooncogene locus with lung cancer. Cancer Res 50:1857 (1990).
25. Weston A, Vineis P, Caporaso NE, Krontiris TG, Lonergan JA, Sugimura H. Racial variation in the distribution of Ha-ras-1 alleles. Mol Carcinog 4:265-268 (1991).
26. Ryberg D, Tefre T, Ovrebo S, Skaug V, Stangeland L, Naalsund A, Baera R, Borresen AL, Haugen A. Ha-ras-1 alleles in Norwegian lung cancer patients. Hum Genet 86:40-44 (1990).
27. Lidereau R, Escot C, Theillet C, Champeme MH. Brunet M, Gest J, Callahan R. High frequency of rare alleles of the human c-Ha-ras-1 proto-oncogene in breast cancer patients. J Natl Cancer Inst 77:697-701 (1986).
28. Corell B, Zoll B. Comparison between the allelic frequency distribution of the Ha-ras 1 locus in normal individuals and patients with lymphoma, breast, and ovarian cancer. Hum Genet 79:255-259 (1988).
29. Sheng ZM, Guerin M, Gabillot M, Speielmann M, Riou G. c-Ha-ras-1 polymorphism in human breast carcinomas: evidence for a normal distribution of alleles. Oncogene Res 2:245-250 (1988).
30. Saglio G, Camaschella C, Giai M, Serra A, Guerrasio A, Peirone B, Gasparini P, Mazza U, Ceppellini R, Biglia N et al. Distribution of Ha-ras-1 proto-oncogene alleles in breast cancer patients and in a control population. Breast Cancer Res Treat 11:147-153 (1988).
31. Honda K, Ishizaki K, Ikenaga M, Toguchida J, Inamoto T, Tanaka K, Ozawa K. Increased frequency of specific alleles of the c-Ha-ras gene in Japanese cancer patients. Hum Genet 79:297-300 (1988).
32. Barkardóttir RB, Jóhannsson ÓT, Arason A, Gundnason V, Egilsson V. Polymorphism of the c-Ha-ras-1 proto-oncogene in sporadic and familial breast cancer. Int J Cancer 44:251-255 (1989).
33. Hall JM, Huey B, Morrow J, Newman B, Lee M, Jones E, Carter C, Buehring GC, King MC. Rare H-ras alleles and susceptibility to human breast cancer. Genomics 6:188-191 (1990).
34. Garrett PA, Hulka BS, Kim YL, Farber RA. H-ras protooncogene polymorphism and breast cancer. Cancer Epidemiol Biomarkers Prev 2:131-138 (1993).
35. Krontiris TG, Devlin B, Karp DD, Robert NJ, Risch N. An association between the risk of cancer and mutations in the H-ras-1 minisatellite locus. N Engl J Med 329:517-523 (1993).
36. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner, SH, Davidson N, Baylin S, Devilee P et al. Mutations in the p53 gene occur in diverse human tumor types. Nature 342:705 (1989).
37. Toguchida J, Yamaguchi T, Dayton SH, Beauchamp RL, Herrera GE, Ishizaki K, Yamamuro T, Meyers PA, Little JB, Sasaki MS et al. Prevalence and spectrum of germ line mutations of the p53 gene among patients with sarcoma. N Engl J Med 326:1301-1308 (1992)
38. Malkin D, Jolly KW, Barbier N, Look AT, Friend SH, Gebhardt MC, Andersen TI, Borresen AL, Li FP, Garber J et al. Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. N Engl J Med 326:1309-1315 (1992).
39. Harris CC. p53: at the crossroads of molecular carcinogenesis and cancer risk assessment. Science 262:1980-1981 (1993).
40. Fields S, Jang SK. Presence of a potent transcription activating sequence in the p53 protein. Science 249:1046-1048 (1990).
41. Chen PL, Chen Y, Bookstein R, Lee WH. Genetic mechanisms of tumor suppression by the human p53 gene. Science 250:1576-1580 (1991).
42. De la Calle-Martin O, Fabregat V, Romero M, Soer J, Vives J, Yague J. AccII polymorphism of the p53 gene. Nucleic Acids Res 18:4963 (1990).
43. Ara S, Lee PS, Hansen MF, Saya H. Codon 72 polymorphism of the TP53 gene. Nucleic Acids Res 18:4961 (1990).
44. Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 7:961-963 (1987).
45. Ahuja HG, Testa MP, Cline MJ. Variation in the protein coding region of the human p53 gene. Oncogene 5:1409-1410 (1990).
46. McDaniel T, Carbone D, Takahashi T, Chumakov P, Chang EH, Pirollo KF, Yin J, Huang Y, Melzer SJ. The Msp 1 polymorphism in intron 6 of p53 (TP53) detected by digestion of PCR products. Nucleic Acids Res 19:4796 (1991).
47. Futreal PA, Barrett JC, Wiseman RW. An alu polymorphism intragenic to the TP53 gene. Nucleic Acids Res 19:6977 (1991).
48. Chumakov PM. Jenkins JR. BstNI/Ncil polymorphism of the human p53 gene (TP53). Nucleic Acids Res 19:6969 (1991).
49. Prosser J, Condie A. Biallelic apal polymorphism of the human p53 gene (TP53). Nucleic Acids Res 19:4799 (1991).
50. Lazar V, Hazard F, Bertin F, Janin N, Belllet D, Bressac B. Simple sequence repeat polymorphism within the p53 gene. Oncogene 8:1703-1705 (1993).
51. Ito T, Seyama T, Hayashi T, Mizuno T, Iwamoto KS, Tsuyama N, Dohi K, Nakamura N. HaeIII polymorphism in intron 1 of the human p53 gene. Hum Genet 93:222 (1994).
52. Felix CA, Brown DL, Mitsudomi T, Ikagaki N, Wong A, Wasserman R, Womer RB, Biegel JA. Polymorphism at codon 36 of the p53 gene. Oncogene 9:327-328 (1994).
53. Carbone D, Chiba I, Mitsudomi T. Polymorphism at codon 213 within the p53 gene. Oncogene 6:1691-1692 (1991).
54. Själander A, Birgander R, Kivelä A, Beckman G. p53 Polymorphisms and haplotypes in different ethnic groups. Hum Hered 45:144-149 (1995).
55. Hahn M, Serth J, Fislage R, Wolfes H, Allhoff E, Jonas U, Pingoud A. Polymerase chain reaction detection of a highly polymorphic VNTR segment in intron 1 of the human p53 gene. Clin Chem 39:549-550 (1993).
56. Runnebaum IB, Tong XW, Moebus V, Heilmann V, Kieback DG, Kreienberg R. Multiplex PCR screening detects small p53 deletions and insertions in human ovarian cancer cell lines. Hum Genet 83:620-624 (1994).
57. Lancaster JM, Brownlee HA, Wiseman RW, Taylor J. p53 Polymorphism in ovarian and bladder cancer. Lancet 346:8968 (1995).
58. Runnebaum IB, Tong XW, Konig R, Hong Z, Korner K, Atkinson EN, Kreienberg R, Keiback DG. p53-Based blood test for p53PIN3 and risk for sporadic ovarian cancer. Lancet 345:994 (1994).
59. Krontiris TG. Oncogenes. N Engl J Med 333:303 (1995).
60. Iwahana H. Orita M, Kanazawa H, Hayashi K, Sekiya T. A new RFLP in intron 1 of the human c-Ha-ras-1 gene and its close relationship with the variable tandem repeats in the region 3′ to the gene. Oncogene 5:1049-1053 (1990).
61. Krontiris TG, DiMartino NA, Colb M, Parkinson DR. Unique allelic restriction fragments of the human Ha-ras locus in leukocyte and tumour DNAs of cancer patients. Nature 313:369-374 (1985).
62. Feinberg AP, Vogelstein B. Hypomethylation of ras oncogenes in primary human cancers. Biochem Biophys Res Commun 111:47-54 (1983).
63. Krontiris TG, DiMartino NA, Colb M, Mitcheson HD, Parkinson DR. Human restriction fragment length polymorphisms and cancer risk assessment. J Cell Biochem 30:319-329 (1986).
64. Altman DG. Practical Statistics for Medical Research. New York:Chapman and Hall, 1991;259-264.
65. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748 (1959).
66. Li CC. Human Genetics. New York:McGraw-Hill, 1961;15-27.
67. Breslow NE, Day NE. The analysis of case-control studies. In: Statistical Methods in Cancer Research, Vol 1 (Bjelke E, Breslow NE, Cole P, Haenszel W, Hill C, Howe G, Miller AB, Modan B, Modan M, Pike M et al, eds). IARC Scientific Publications No 32. Lyon:International Agency for Research on Cancer, 1980;182.
68. Kuritz SJ, Landis JR. Summary attributable risk estimation from unmatched case-control data. Stat in Med 7:507-517 (1988).
69. Prosser J, Thompson AM, Cranston G, Evans HJ. Evidence that p53 behaves as a tumour suppressor gene in sporadic breast tumours. Oncogene 5:1573-1579 (1990).
70. Prosser J, Elder PA, Condie A, MacFadyen I, Steel CM, Evans HJ. Mutations in p53 do not account for heritable breast cancer: a study in five affected families. Br J Cancer 63:181-184 (1991).
71. Warren W, Eeles RA, Ponder BAJ, Easton DF, Averill D, Ponder MA. No evidence for germline mutations in exons 5-9 of the p53 gene in 25 breast cancer families. Oncogene 7:1043-1046 (1992).
72. Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, King MC. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250:1684-1689 (1990).
73. Weston A, Willey JC, Modali R, Sugimura H, McDowell EM, Resau J, Light B, Haugen A, Mann DL, Trump BF et al. Differential DNA sequence deletions from chromosomes 3, 11, 13 and 17 in squamous cell carcinoma, large cell carcinoma and adenocarcinoma of the human lung. Proc Natl Acad Sci USA 86:5099 (1989).
74. Ludwig CU, Raefle G, Dalquen P, Stulz P, Stahel R, Obrecht JP. Allelic loss on the short arm of chromosome 11 in non-small-cell lung cancer. Int J Cancer 49:661-665 (1991).
75. Scrable HJ, Witte DP, Lampkin BC, Casvenee WK. Chromosomal localization of the human rhabdomyosarcomas locus by mitotic recombination mapping. Nature 329:645-647 (1987).
76. Trepicchio WL, Krontiris TG. Members of the rel/NF-κβ family of transcriptional regulatory factors bind the H-ras-I minisatellite DNA sequence. Nucleic Acids Res 20:2427-2434 (1992).
77. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855 (1994).
78. Weston A, Pan C-F, Ksieski HB, Wallenstein S, Berkowitz GS, Tartter PI, Bleiweiss IJ, Brower ST, Senie RT, Wolff, MS. p53 Haplotype determination in breast cancer. Submitted to Cancer Epidemiol Biomarkers Prev 6:105-112 (1997).
79. Conway K, Edmiston SN, Hulka BS, Garrett PA, Liu ET. Allele length and minisatellite variant repeat analyses of the Ha-ras VNTR in a breast cancer case-control study. Proc Am Assoc Cancer Res 37:A1764 (1996).
80. Phelan CM, Rebbeck TR, Weber BL, Devilee P, Rutledge MH, Lynch HT, Lenoir GM, Stratton MR, Easton DF, Ponder BA et al. Ovarian cancer risk in BRCA1 carriers is modified by HRAS1 variable number of tandem repeat (VNTR) locus. Nat Genet 12:309-311 (1996).
81. Själander A, Birgander R, Hallmans G, Cajander S, Lenner P, Athlin L, Beckman G, Beckman L. p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis 17:1313-1316 (1996).